JP Morgan Chase’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-66,500
Closed -$2.58M 5938
2019
Q1
$2.58M Buy
+66,500
New +$2.03M ﹤0.01% 3159
2018
Q2
Sell
-111,000
Closed -$7.55M 5650
2018
Q1
$7.55M Buy
111,000
+51,000
+85% +$3.82M ﹤0.01% 2232
2017
Q4
$5.93M Hold
60,000
﹤0.01% 2543
2017
Q3
$7.04M Buy
+60,000
New +$5.58M ﹤0.01% 2285
2016
Q4
Sell
-42,500
Closed -$2.85M 5099
2016
Q3
$2.85M Buy
+42,500
New +$2.15M ﹤0.01% 2585

Other funds holding PBYI

JP Morgan Chase's PBYI Position: Q2 2026 in Review

JP Morgan Chase reduced its Puma Biotechnology (PBYI) stake by 4.3% in Q2 2026, selling an estimated $68.7K and leaving 211,339 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #4289.

JP Morgan Chase first reported a position in PBYI in Q2 2013 and has held it in 53 quarters since. The position peaked at $65.8M in Q3 2014. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • JP Morgan Chase held 211,339 shares of Puma Biotechnology worth $1.73M as of Q2 2026.
  • JP Morgan Chase sold 9,385 Puma Biotechnology shares in Q2 2026, an estimated $68.7K.
  • Puma Biotechnology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4289 holding.
  • JP Morgan Chase first reported a position in Puma Biotechnology in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Puma Biotechnology position peaked at $65.8M in Q3 2014.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.